D. Rubino

发表

Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM‐DM studies

C. Apovian, R. Fain, K. Palmer, 2016, Diabetes, obesity & metabolism.

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

T. Wadden, S. Calanna, M. Thomsen, 2021, Diabetes, obesity & metabolism.

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

T. Wadden, M. Davies, R. Kushner, 2020, Obesity.

Safety and tolerability review of lorcaserin in clinical trials

F. Greenway, R. Fain, D. Rubino, 2016, Clinical obesity.

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

F. Greenway, T. Wadden, J. Rosenstock, 2021, JAMA.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

D. Lau, D. Rubino, M. Kankam, 2021, The Lancet.

Age no Impediment to Effective Weight Loss with Liraglutide 3.0 Mg: Data from Two Randomized Trials

H. Wyatt, R. Kushner, J. Wilding, 2018, XXI I Congresso Brasileiro de Nutrologia.

Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes

K. Fujioka, L. Aronne, T. Wadden, 2020, International Journal of Obesity.

Isolated hyponatremia after transsphenoidal pituitary surgery.

E. Oldfield, D. Rubino, B. Olson, 1995, The Journal of clinical endocrinology and metabolism.

Use of herbal therapies by adults seen in an ambulatory care research setting: an exploratory survey.

J. Wootton, L. Mccullagh, R. Wesley, 2000, Journal of alternative and complementary medicine.

Pathophysiology of hyponatremia after transsphenoidal pituitary surgery.

E. Oldfield, D. Rubino, B. Olson, 1997, Journal of neurosurgery.

Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses

J. Deanfield, R. Kushner, W. Garvey, 2022, Diabetes, obesity & metabolism.

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial

F. Greenway, T. Wadden, P. O'Neil, 2021 .

A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss

Heather B. Blunt, Pamela J. Bagley, K. Saunders, 2021, Obesity.

Specificity of screening tests for Cushing's syndrome in an overweight and obese population.

L. Nieman, N. Sinaii, D. Rubino, 2009, The Journal of clinical endocrinology and metabolism.

A direct comparison of quality of life in obese and Cushing's syndrome patients.

L. Nieman, T. Nansel, D. Rubino, 2013, European journal of endocrinology.

Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism.

L. Nieman, N. Sinaii, D. Rubino, 2007, The Journal of clinical endocrinology and metabolism.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Raymond L. Forbes, A. Astrup, F. Greenway, 2017, The Lancet.

Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

R. Kushner, W. Garvey, J. Deanfield, 2022, EClinicalMedicine.

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

T. Wadden, P. O'Neil, T. Bailey, 2021, JAMA.

Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes

Peter W. Tuerk, K. Fujioka, T. Wadden, 2016, Obesity.

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

T. Wadden, P. Auerbach, D. Rubino, 2020, Obesity.

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)

Dennis D. Kim, E. Dunayevich, C. Apovian, 2013, Obesity.

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

D. Lau, K. Pietiläinen, R. Batterham, 2021, The Lancet.

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

I. Lingvay, S. Wharton, D. Dicker, 2021, Postgraduate medicine.

Weight History in Clinical Practice: The State of the Science and Future Directions

K. Saunders, J. Batsis, R. Kushner, 2020, Obesity.

Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program

P. O'Neil, D. Rubino, 2022, Postgraduate medicine.

Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial.

Peter W. Tuerk, K. Fujioka, T. Wadden, 2017, Journal of diabetes and its complications.

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

T. Wadden, P. Auerbach, D. Rubino, 2020, Obesity Facts.

Biopsychosocial Modifiers of Obesity

D. Rubino, 2018, Bariatric Endocrinology.

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

J. Rosenstock, F. Knop, V. Aroda, 2023, The Lancet.

A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity

R. V. Overgaard, S. Wharton, M. S. Larsen, 2023, Diabetes, obesity & metabolism.

Cortisol, obesity and the metabolic syndrome: A cross-sectional study of obese subjects and review of the literature

L. Nieman, N. Sinaii, D. Rubino, 2012, Obesity.

A review of topiramate and phentermine: a combined therapeutic approach for obesity

K. Gadde, D. Rubino, 2012 .

Specificity of screening tests for Cushing's syndrome in an overweight and obese population.

L. Nieman, N. Sinaii, D. Rubino, 2009, The Journal of clinical endocrinology and metabolism.

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

F. Greenway, T. Wadden, P. O'Neil, 2022, JAMA.